Tuesday, September 15, 2015

Pasting test

This is a test to see what happens when pasting from Word to Blogger compared to pasting from Word to Notepad to Blogger.

In both cases the final paste is to blogger in the compse window and then checked in the html window

First: Word to blogger



Hepatitis C in Children
—Alan Franciscus, Editor-in-Chief
It is estimated that Hepatitis C (HCV) occurs in about 0.15% of 6-11 year-olds and 0.4% of 12-19 year-olds.  It is estimated that there are 23,000 to 46,000 children in the US with HCV.1  The actual number of children with HCV is unknown because children are not routinely tested for it. 

Prior to 1992, the most common transmission route for HCV in children was through blood transfusion, blood products, and organ transplantation.  Now that blood products and organs are screened for hepatitis C the most frequent transmission of hepatitis C in infants is mother-to-child transmission.  The second most common transmission route in children and teenagers is in those who share equipment to inject drugs (needles, cookers, cotton, water, etc.)  
Transmission of HCV from an HCV-infected mother-to-infant occurs about 6% of the time.  It can occur up to 10% of the time if a mother is coinfected with HIV and hepatitis C.  Also, a high viral load increases the risk of mother-to-infant transmission.   Unfortunately, there are no effective strategies or drugs to prevent the transmission of HCV from mother to child.   

When a baby is born to an HCV-infected mother, the child will acquire the mother’s HCV antibodies.  For this reason, the child will not be tested for HCV antibodies for 18 months.  This is the period that it takes for the baby’s body to clear out the mother’s antibodies.


Second: Word to Notepad, then notepad to blogger

Hepatitis C in Children
—Alan Franciscus, Editor-in-Chief
It is estimated that Hepatitis C (HCV) occurs in about 0.15% of 6-11 year-olds and 0.4% of 12-19 year-olds.  It is estimated that there are 23,000 to 46,000 children in the US with HCV.1  The actual number of children with HCV is unknown because children are not routinely tested for it. 

Prior to 1992, the most common transmission route for HCV in children was through blood transfusion, blood products, and organ transplantation.  Now that blood products and organs are screened for hepatitis C the most frequent transmission of hepatitis C in infants is mother-to-child transmission.  The second most common transmission route in children and teenagers is in those who share equipment to inject drugs (needles, cookers, cotton, water, etc.)  
Transmission of HCV from an HCV-infected mother-to-infant occurs about 6% of the time.  It can occur up to 10% of the time if a mother is coinfected with HIV and hepatitis C.  Also, a high viral load increases the risk of mother-to-infant transmission.   Unfortunately, there are no effective strategies or drugs to prevent the transmission of HCV from mother to child.   

When a baby is born to an HCV-infected mother, the child will acquire the mother’s HCV antibodies.  For this reason, the child will not be tested for HCV antibodies for 18 months.  This is the period that it takes for the baby’s body to clear out the mother’s antibodies.

Friday, July 31, 2015

Miracle Dog Saves The Day

FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

The U.S. Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) NS5A inhibitor Daklinza (daclatasvir) to be used in combination with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C. This is the first hep C regimen ever to be specifically approved for genotype 3, and it improves cure rates over other currently available treatments. However, the cure rate anticipated for those with cirrhosis is still quite poor.

Twelve weeks of once-daily regimen is recommended.

An estimated 12 percent of Americans with hep C are infected with genotype 3. It is the second most common genotype in the United States, behind genotype 1, which makes up about 70 percent of the U.S. epidemic. Read more....

Hepatitis C warning from the state

 A week ago we told you that Hepatitis C was almost at epidemic status.  Now the state health department says beware it

A week ago, we told you that Hepatitis C was almost at epidemic status. Now the state health department says beware it's there. More than 100,000 people in Tennessee are living with it and don't even know they're infected, it could be you.

We talked to a girl who has it. She was a good girl who got in with the wrong crowd. Now she's got a life threatening illness that could steal her away from her children. By the way, we'll call her Amy since she wants to keep her identity hidden. Read more....

Gilead Sales Soar on Hepatitis Drugs - Sales of Harvoni, Sovaldi top estimates despite increased competition

Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected sales of the newer Harvoni.

For the year, the company again raised its guidance for net product sales, this time by $1 billion, and now expects sales to reach $29 billion to $30 billion.

Shares of Gilead, up 24% over the past year, rose 3.2% to $116.99 in recent after-hours trading.

Read more...http://www.wsj.com/articles/gilead-sales-soar-on-hepatitis-drugs-1438114949

Thursday, July 23, 2015

The Top 5 Best Analyst Coverage on Gilead Sciences, Inc (GILD) Ahead of Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) will release second quarter earnings on Tuesday, July 28. The biopharmaceutical giant is most known for its hepatitis C drugs, Harvoni and Sovaldi. Several analysts weighed in on Gilead after the company posted a strong earnings report in May. Here are the top 5 analysts to follow ahead of the upcoming earnings release:

1. Alan Carr of Needham most recently weighed in on Gilead on May 1, reiterating a Buy rating on the stock with an unchanged priced target of $120. Carr made the rating in light of the company’s first quarter earnings report in which the company posted better-than-expected results. The analyst attributed the strong earnings to Harvoni and to an adjustment made in Branded Prescription Fee. At the time, the analyst correctly predicted that Harvoni would be approved in Japan later in the year. He also commented, “Top-line results from Phase 3 ASTRAL program testing 12-wk sof/ GS-5816 [a pipeline drug aimed at chronic HCV infection] are expected in 3Q15, followed by NDA submission in 4Q15.” The pipeline drug is still in Phase 3 testing.

Alan Carr has rated Gilead 15 times since February 2012, earning a 100% success rate recommending the stock and a +55.4% average return per GILD rating when measured over a one-year horizon and no benchmark.


READ MORE...
http://www.smarteranalyst.com/2015/07/23/top-5-analysts-to-watch-ahead-of-gilead-sciences-incs-gild-earnings/

New Drug Combination Treats Hepatitis C Patients Also Infected With HIV

Roughly 20 percent to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both bloodborne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV.

The study, published online in the New England Journal of Medicine, found the combination of HCV drugs daclatasvir and sofosbuvir -- both pills -- cured HCV in 97 percent of patients also infected with HIV.

"In many HCV/HIV co-infected patients, HCV therapies can have a strong interaction with HIV medications that complicate or potentially exclude them from HCV treatment," says David Wyles, MD, lead author of the study in the Division of Infectious Diseases. "This study is novel because it shows the new drug combination was not compromised when used with a wide range of HIV medications, increasing the number of HCV/HIV patients who can be treated without modifying their HIV medications."

READ MORE...http://www.infectioncontroltoday.com/news/2015/07/new-drug-combination-treats-hepatitis-c-patients-also-infected-with-hiv.aspx